title: Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder.
abstract: BACKGROUND
  Electroencephalographic (EEG) sleep slow wave activity (SWA; EEG power between 0.6 and 4Hz) has been proposed as a marker of central synaptic plasticity. Decreased generation of sleep slow waves--a core feature of sleep in depression--indicates underlying plasticity changes in the disease. Various measures of SWA have previously been used to predict antidepressant treatment response. This study examined the relationship between baseline patterns of SWA in the first two NREM episodes and antidepressant response to an acute infusion of the N-methyl-d-aspartate (NMDA) antagonist ketamine.
  
  
  METHODS
  Thirty patients (20M, 10F, 18-65) fulfilling DSM-IV criteria for treatment-resistant major depressive disorder (MDD) who had been drug-free for two weeks received a single open-label infusion of ketamine hydrochloride (.5mg/kg) over 40 min. Depressive symptoms were assessed with the Montgomery-Asberg Depression Rating Scale (MADRS) before and after ketamine infusion. Sleep recordings were obtained the night before the infusion and were visually scored. SWA was computed for individual artifact-free NREM sleep epochs, and averaged for each NREM episode. Delta sleep ratio (DSR) was calculated as SWA(NREM1)/SWA(NREM2).
  
  
  RESULTS
  A significant positive correlation was observed between baseline DSR and reduced MADRS scores from baseline to Day 1 (r=.414, p=.02).
  
  
  CONCLUSIONS
  The sample size was relatively small (N=30) and all subjects had treatment-resistant MDD, which may limit the generalizability of the findings. Further studies are needed to replicate and extend this observation to other patient groups.
  
  
  CONCLUSIONS
  DSR may be a useful baseline predictor of ketamine response in individuals with treatment-resistant MDD.
authors.affiliation: Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Wallace C
authors.initials: WC
authors.lastname: Duncan
authors.forename: Jessica
authors.initials: J
authors.lastname: Selter
authors.forename: Nancy
authors.initials: N
authors.lastname: Brutsche
authors.forename: Simone
authors.initials: S
authors.lastname: Sarasso
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Zarate
mesh_terms: D000293:Adolescent; D000328:Adult; D000339:Affect / Q000187:drug effects*; D000368:Aged; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000503:physiopathology*; D004351:Drug Resistance; D004569:Electroencephalography; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007649:Ketamine / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016202:N-Methylaspartate / Q000494:pharmacology / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012890:Sleep / Q000502:physiology*; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D015415:Biomarkers; D018691:Excitatory Amino Acid Antagonists; D016202:N-Methylaspartate; D007649:Ketamine